Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer (Q44889720)

7 December 2017

title

Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. (English)

1 reference

7 December 2017

1 reference

1 reference

Tiffany NM

1

1 reference

7 December 2017

Wersinger EM

series ordinal

2

1 reference

7 December 2017

Garzotto M

series ordinal

3

1 reference

7 December 2017

Beer TM

series ordinal

4

1 reference

7 December 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

7 December 2017

1 reference

7 December 2017

volume

63

1 reference

7 December 2017

issue

5

1 reference

7 December 2017

page(s)

934-939

1 reference

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

Morphometric evidence for bone resorption and replacement in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

Markers of bone turnover for the management of patients with bone metastases from prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

Effects of the Bisphosphonate Olpadronate in Patients With Carcinoma of the Prostate Metastatic to the Skeleton

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

Endothelium-derived factors as paracrine mediators of prostate cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

The McGill Pain Questionnaire: Major properties and scoring methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLOGY.2003.12.022

10.1016/J.UROLOGY.2003.12.022

7 January 2021

Identifiers

DOI

1 reference

7 December 2017

1 reference